Johnson & Johnson
- Open
- 259.12
- Day high
- 259.90
- Day low
- 253.17
- Prev close
- 258.51
- Volume
- 7.0M
- Mkt cap
- $611.4B
- P/E (TTM)
- 29.3
- EPS (TTM)
- $8.67
- P/B
- 7.5
- P/S
- 6.3
- Yield
- 2.06%
- Per share
- $5.24
- ▼Insiders net selling -$2.4M over the last 3 months (0 open-market buys, 1 sale)
- 🏛Institutions mixed (13F)
Johnson & Johnson (JNJ) is a Healthcare company listed on NYSE. The stock is up 63% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 1 sale (SEC Form 4). Drillr has 2 published research articles covering JNJ.
Johnson & Johnson (JNJ) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 7 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
JNJ earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 14, 2026 | $2.68 | $2.70 | +0.7% | $24.1B | +1.9% |
| Jan 21, 2026 | $2.46 | $2.46 | +0.0% | $24.6B | +1.7% |
| Oct 14, 2025 | $2.76 | $2.80 | +1.4% | $24.0B | +1.0% |
| Jul 16, 2025 | $2.68 | $2.77 | +3.4% | $23.7B | +3.9% |
| Apr 15, 2025 | $2.58 | $2.77 | +7.4% | $21.9B | +1.6% |
| Jan 22, 2025 | $1.99 | $2.04 | +2.5% | $22.5B | +0.4% |
| Oct 15, 2024 | $2.21 | $2.42 | +9.5% | $22.5B | +1.3% |
| Jul 17, 2024 | $2.71 | $2.82 | +4.1% | $22.4B | +0.5% |
| Apr 16, 2024 | $2.64 | $2.71 | +2.7% | $21.4B | -0.1% |
| Jan 23, 2024 | $2.27 | $2.29 | +0.9% | $21.4B | +1.9% |
| Oct 17, 2023 | $2.52 | $2.66 | +5.6% | $21.4B | +7.7% |
| Jul 20, 2023 | $2.61 | $2.80 | +7.3% | $21.5B | -12.6% |
JNJ insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 12, 2026 | Wengel Kathryn Eofficer: EVP, Chief TO and Risk Officer | Sell | 10,000 | $241.15 |
| Jun 12, 2026 | Wengel Kathryn Eofficer: EVP, Chief TO and Risk Officer | Option | 10,000 | $115.67 |
| Jun 11, 2026 | Woods Eugene A.director | Grant | 161 | — |
| Jun 11, 2026 | Pinto Daniel Edirector | Grant | 134 | — |
| Jun 11, 2026 | HEWSON MARILLYN Adirector | Grant | 215 | — |
| May 4, 2026 | REED JOHN Cofficer: EVP, Innovative Medicine, R&D | Option | 25,255 | — |
| May 4, 2026 | REED JOHN Cofficer: EVP, Innovative Medicine, R&D | Tax | 11,002 | $229.85 |
| Apr 27, 2026 | WEINBERGER MARK Adirector | Grant | 975 | — |
| Apr 27, 2026 | Doudna Jennifer Adirector | Grant | 975 | — |
| Apr 27, 2026 | Beckerle Mary Cdirector | Grant | 975 | — |
| Apr 27, 2026 | Pinto Daniel Edirector | Grant | 1,712 | — |
| Apr 27, 2026 | Woods Eugene A.director | Grant | 975 | — |
| Apr 27, 2026 | Johnson Paula Adirector | Grant | 975 | — |
| Apr 27, 2026 | HEWSON MARILLYN Adirector | Grant | 975 | — |
| Apr 27, 2026 | McClellan Mark B.director | Grant | 975 | — |
Source: JNJ SEC Form 4 filings, latest Jun 12, 2026. For informational purposes only — not investment advice.
See the full JNJ insider & 13F page →JNJ research & analysis
Pharma Tariffs: Buy LLY & AMGN, Sell PFE & MRK — Here's Why
Trump policies eroding Europe's pharma lead via tariffs favor US manufacturing-heavy Eli Lilly and Amgen, with strong growth and margins, while Pfizer and Merck's global chains invite cost squeezes. J&J and AbbVie sit in the middle with diversification. Rank: Buy LLY/AMGN, sell PFE/MRK.
LLYAMGNABBVPharma Tariffs: LLY and AMGN Win While PFE and MRK Face Margin Squeeze
Trump's pharma import tariffs shield U.S.-focused drugmakers like Eli Lilly and Amgen from cost hikes while pressuring import-reliant Pfizer and Merck. Analysis ranks six majors by exposure, highlighting financials and guidance. Domestic winners eye margin expansion amid onshoring push.
LLYAMGNABBV
Johnson & Johnson company profile
Overview
Johnson & Johnson (NYSE:JNJ) is one of the world's largest and most diversified healthcare companies, founded in 1886 by the Johnson brothers in New Brunswick, New Jersey. Originally starting as a manufacturer of ready-to-use sterile surgical dressings, the company has evolved over nearly 140 years into a global healthcare conglomerate. Today, J&J operates as a two-sector company focused on Innovative Medicine (pharmaceuticals) and MedTech (medical devices), having completed the spin-off of its Consumer Health division (Kenvue) in 2023. The company serves patients, healthcare professionals, and consumers across more than 175 countries worldwide, maintaining its position as a healthcare industry leader through continuous innovation and strategic acquisitions.
Business
Johnson & Johnson operates in two primary business segments following its strategic transformation into a focused healthcare company: Innovative Medicine (Pharmaceutical Segment) - approximately 65% of total revenue - develops, manufactures, and markets prescription medications across multiple therapeutic areas. The pharmaceutical industry involves years of research and development to discover new drugs, followed by extensive clinical trials to prove safety and efficacy before regulatory approval. Key therapeutic areas include oncology (cancer treatments), immunology (autoimmune diseases), neuroscience (brain and nervous system disorders), and infectious diseases. Major products include DARZALEX for multiple myeloma (a blood cancer), STELARA for inflammatory conditions like psoriasis and Crohn's disease, TREMFYA for psoriasis and inflammatory bowel disease, and SPRAVATO for treatment-resistant depression. MedTech (Medical Technology Segment) - approximately 35% of total revenue - designs, manufactures, and sells medical devices, surgical equipment, and related technologies used by healthcare professionals. This segment includes electrophysiology products for treating heart rhythm disorders, neurovascular devices for stroke treatment, orthopedic implants for joint replacement surgeries, surgical instruments and robotics, and vision care products including ACUVUE contact lenses. The medical device industry requires significant engineering expertise and regulatory compliance, with products ranging from simple disposable items to complex robotic surgical systems. The company has strategically exited the consumer health business, which previously included well-known brands like TYLENOL, BAND-AID, and JOHNSON'S baby products, to focus exclusively on higher-growth, higher-margin prescription healthcare markets.
Revenue model
Johnson & Johnson generates revenue through multiple business models across its two operating segments: Product Sales Revenue Model forms the core of both segments. In Innovative Medicine, the company sells prescription drugs to wholesalers, distributors, hospitals, and healthcare systems, who then distribute to pharmacies and healthcare providers. Pharmaceutical pricing is complex, involving negotiations with insurance companies, government payers, and pharmacy benefit managers. The company benefits from patent protection on newer drugs, allowing premium pricing until generic competition enters. In MedTech, revenue comes from selling medical devices, surgical instruments, and consumables to hospitals, surgery centers, and healthcare providers, typically through direct sales forces or distributor networks. Factors that increase margins include successful new product launches with strong clinical data, patent protection on innovative medicines, favorable drug pricing negotiations, operational efficiency improvements, and premium positioning in high-growth therapeutic areas. The company's scale allows for significant R&D investment and manufacturing efficiencies. Market expansion in emerging countries and successful clinical trial outcomes for pipeline products also drive margin expansion. Factors that decrease margins include patent expirations leading to generic competition (notably affecting STELARA), government pricing pressures through programs like Medicare drug price negotiations, increased R&D costs for complex drug development, manufacturing and supply chain disruptions, competitive pricing pressure in medical devices, and regulatory compliance costs. Currency fluctuations in international markets and potential litigation settlements also impact profitability. The company faces particular pressure from biosimilar competition as several key drugs lose patent protection.
Competitive moat
Johnson & Johnson possesses a strong but evolving competitive moat built on several key advantages. The company benefits from significant regulatory barriers to entry in both pharmaceuticals and medical devices, where competitors must navigate years of clinical trials and regulatory approvals. Its scale advantages in R&D spending (nearly $15 billion annually) and global manufacturing create substantial barriers for smaller competitors. The switching costs in healthcare are considerable - doctors develop familiarity with specific drugs and devices, and changing treatments involves risk and retraining. J&J's established relationships with healthcare systems, built over decades, provide distribution advantages. The company's diversified portfolio across multiple therapeutic areas reduces dependence on any single product and provides cross-selling opportunities. However, the moat faces significant challenges. Patent cliffs represent the most immediate threat, with major products like STELARA facing biosimilar competition that can erode 80-90% of sales over several years. The pharmaceutical industry's innovation requirements mean the company must continuously develop new products to replace those losing patent protection. Pricing pressure from government programs like Medicare drug price negotiations and international healthcare systems increasingly constrains pricing power. Competitive threats come from large pharmaceutical companies like Pfizer and Merck in drug development, and medical device specialists like Medtronic and Abbott in MedTech. Emerging biotechnology companies with novel approaches can disrupt established therapeutic areas. The company's moat remains meaningful but requires constant reinforcement through innovation and strategic acquisitions to maintain competitive positioning.
Risks & safety
Johnson & Johnson demonstrates a strong margin of safety with solid financial fundamentals, though facing some near-term headwinds: • Financial Strength: Strong balance sheet with $24.1 billion in cash and short-term investments, current ratio of 1.11, and manageable debt-to-equity ratio of 0.51. Operating cash flow of $24.3 billion provides substantial financial flexibility. • Valuation Metrics: Trading at reasonable multiples with P/E ratio of 24.5x (2024), EV/EBITDA of 14.4x, and price-to-book of 4.8x. Graham number of $62.48 suggests potential undervaluation at current levels. • Dividend Safety: 62 consecutive years of dividend increases, supported by strong free cash flow generation of $19.8 billion annually, indicating commitment to shareholder returns. • Concerns: Significant litigation exposure from talc-related lawsuits, though management has proposed a $6.5 billion settlement. STELARA patent expiration poses revenue headwinds. Some quarters show elevated debt levels and working capital pressures. • Growth Outlook: Management guidance of 3%+ operational sales growth with pipeline products like CARVYKTI and TREMFYA expansion providing growth drivers to offset patent losses.
Recent development
Johnson & Johnson has undergone significant strategic transformation over the past few years, positioning itself as a focused healthcare company. The most significant change was completing the spin-off of its Consumer Health division in 2023, creating Kenvue as a separate public company and allowing J&J to concentrate exclusively on higher-growth pharmaceutical and medical device markets. The company has pursued an aggressive acquisition strategy, deploying over $18 billion in strategic acquisitions during 2024 alone. Key acquisitions include Abiomed for heart pump technologies, Shockwave Medical for cardiovascular devices, and Intra-Cellular Therapies to strengthen its neuroscience portfolio. These acquisitions demonstrate the company's focus on high-innovation, high-growth therapeutic areas. In pharmaceuticals, J&J has built a leading oncology franchise with multiple myeloma treatments DARZALEX, CARVYKTI, and TECVAYLI showing strong growth. The company has expanded TREMFYA's indications beyond psoriasis into inflammatory bowel disease, positioning it as a potential replacement for STELARA as biosimilar competition intensifies. SPRAVATO for treatment-resistant depression exceeded $1 billion in annual sales, establishing J&J's presence in neuroscience. The MedTech segment has focused on advanced surgical technologies, including robotic surgery platforms like OTTAVA and VELYS, and expanding the electrophysiology portfolio for heart rhythm disorders. The company has also strengthened its cardiovascular device portfolio through strategic acquisitions, targeting high-growth segments within medical technology. Management has committed to $55 billion in U.S. manufacturing investment over four years, demonstrating confidence in long-term growth and addressing supply chain resilience. The company continues to invest heavily in R&D, maintaining spending near $15 billion annually to fuel its innovation pipeline.
JNJ company profile · for informational purposes only — not investment advice.
Track JNJ with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free